ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis

Nephrology Dialysis Transplantation

Volumn 16, Issue 8, 2001, Pages 1631-1637

  Nowack, Rainer ^a,b   Grab, Ilona ^a   Flores Suarèz, Luis Felipe ^a   Schnülle, Peter ^a   Yard, Benito ^a   Van Der Woude, Fokko J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE   (Germany)

Author keywords

IgG subclasses; Prognostic value of ANCA; Relapses; Soluble CD14; Systemic vasculitis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CD14 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; MYELOBLASTIN ANTIBODY; MYELOPEROXIDASE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; ASSAY; BLOOD ANALYSIS; CHRONICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; MEASUREMENT; PARAMETER; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SOLUBILITY; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0034870832     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.8.1631     Document Type: Article

References (22)

1. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC BCR Project for ANCA Assay Standardization
2. Autoantibodies to neutrophils and monocytes: A new tool for diagnosis and a marker of disease activity in Wegener's granulomatosis
3. Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides
4. Serial ANCA testing has limited value during the follow-up of disease activity in patients with ANCA-associated vasculitis
5. IgG subclass distribution of autoantibodies to neutrophil cytoplasmic antigens in systemic vasculitis
6. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders
7. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis, a predominant role for the IgG3 subclass of ANCA
8. CD14+ + monocytes, CD14+ CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy
9. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis
10. Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody
11. Screening for antineutrophil cytoplasmic antibodies (ANCA): Is indirect immunofluorescence the method of choice?
12. IgG subclasses of antineutrophil autoantibodies (ANCA)
13. Limited prognostic value of changes in anti-neutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis
14. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis
15. Association between active Wegener's granulomatosis and anti-cytoplasmic antibodies
16. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre
17. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides
18. ANCA and predicting relapse in systemic vasculitis
19. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis
20. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis
21. IgG subclass distribution and relative functional affinity of anti-myeloperoxidase antibodies in systemic vasculitis at presentation and during follow-up
22. ANCA upregulate CD14 and CD18 on monocytes in vitro